The normal increase in pulmonary vascular resistance in response to hypoxaemia occurs in an exaggerated form in the newborn infant. Pulmonary artery pressure rises to systemic levels with the reappearance of a transitional pattern of circulation (James and Rowe, 1957; Rudolph and Yuan, 1966) . In infants with severe hyaline membrane disease, this response increases the right-to-left shunting of blood leading to increasing hypoxaemia, which is unresponsive to either increases in the fractional inspired oxygen concentration (F1o2) or to alterations in mechanical ventilator settings (Chu et al., 1967; Stahlman et al., 1972; Gersony et al., 1976) . Tolazoline hydrochloride has been suggested as a therapeutic agent for dilating the pulmonary arteries which might be used to improve arterial oxygenation (Cotton, 1965; Korones and Eyal, 1975; Goetzman et al., 1976) . This report describes our experience with the use of tolazoline in 20 consecutively admitted infants with severe hypoxaemia due to hyaline membrane disease. Patients and methods Twenty critically ill preterm newborn infants with severe hyaline membrane disease born between October 1976 and July 1977, developed persistent severe hypoxaemia while being mechanically ventilated, and were given 48 doses of tolazoline. The clinical details of the infants are shown in Table 1 None of the infants had polycythaemia or hypoglycaemia, and all were managed by methods previously described (Blake et al., 1973) . Six babies had coagulation abnormalities, 4 disseminated intravascular coagulation, and 2 had less specific abnormalities. Two infants had severe rhesus isoimmunisation requiring exchange transfusions.
The infants were all ventilated via an oroendotracheal tube with a constant flow pressure-controlled ventilator (Bourns BP 200). Mean peak airway pressure (PAP) was 29 cm (range 20-40) H20; mean end expiratory pressure (EEP) was 3 5 cm (range 0-5) H20; median inspiration/expiration ratio (I/E ratio) 1:1 (range 1:2-3:1); mean respiratory frequency (f) 30/min (range 25-40/min).
Seventeen infants had umbilical artery catheters sited in the lower abdominal aorta. Fifteen of the catheters had oxygen electrodes at their tips (Searle), allowing the continuous monitoring of arterial oxygen tension (Pao2) (Conway et al., 1976) . In all infants, frequent blood-gas analyses were performed* on arterial samples obtained from either the arterial catheters or peripheral arteries.
The indication for giving the first dose of tolazoline was deteriorating hypoxaemia in the presence of an inspired oxygen concentration of 100% (Fo02 = 1*0) and the failure to respond to various manipulations of ventilator settings intended to raise Pao2 (Blake et al., 1973; Herman and Reynolds, 1973 mmHg, and in the remaining infant the Pao2 was 66 mmHg. Subsequent doses of tolazoline were given in 11 infants, who responded to the first dose, and in whom hypoxaemia recurred. Chest x-rays were taken before the use of tolazoline if time allowed, so as to exclude pneumothorax as a cause for the infant's deterioration. In 7 infants, pancuronium bromide in a dose sufficient to paralyse spontaneous respiration (0 03-0 '05 mg/kg repeated as necessary) was given without improvement before the administration of tolazoline. The dose of tolazoline hydrochloride was 1-2 mg/kg body weight given over 30 seconds, into a scalp vein (10 infants), into another vein (2 infants), or into the umbilical artery (8 infants).
Ventilator settings were recorded before and after each dose of tolazoline. In the 15 infants in whom the abdominal aortic Pao2 was recorded continuously, the records were analysed to determine the Pao2 one min before and the peak Pao2 within 10 min after the administration of tolazoline. In addition blood-gas analysis was performed before and after each dose of tolazoline.
Mean airway pressure (MAP) was calculated for each of the ventilator settings, using the formula (PAP x inspired ratio) + (EEP x expired ratio) inspired + expired ratio and changes in Pao2 were determined from the bloodgas and abdominal aortic oxygen electrode data.
MAP has been shown to correlate well with alveolar arterial oxygen difference at slow respiratory rates (Herman and Reynolds, 1973) , and so was used to measure changes in ventilation which might have contributed to changes in Pao2. Changes in pH, Paco2, and base excess (BE) were also noted.
Blood pressure was measured by ultrasound using a Doppler (1 infant) or by a transducer (Hewlett Packard) attached to the umbilical arterial catheter (12 infants).
Tolazoline administration is followed by peripheral vasodilatation (Grover et al., 1961) , and this was apparent in our infants. In 13 of them infusion of either whole blood, normal saline, or 5 % sodium bicarbonate was needed after the administration of tolazoline to maintain an adequate circulating blood volume and a normal blood pressure.
The data obtained relating to each dose of tolazoline were analysed, using Student's paired or unpaired t test, as appropriate.
Results
Data obtained from continuously recorded abdominal aortic Pao2 are summarised in Table 2 . An example of such a record showing the response to tolazoline from which these data were obtained is shown in the Figure. Data obtained from analysis of samples of arterial blood are summarised in In the 9 infants who were not shown subsequently to have intracranial haemorrhage or pneumothorax (group A), the mean rise of 39 mmHg in abdominal aortic Pao2 was significantly greater than in the 6 infants with either intracranial haemorrhage or pneumothorax (group B) in whom the mean rise in abdominal aortic Pao2 was 8 mmHg (P<0 01). Thl response to tolazoline was more marked after the first dose, the mean rise in abdominal aortic Pao2 in all patients being 39 mmHg. In group A the mean rise of 56 mmHg was significantly greater than in group B, in which the mean rise was 14 mmHg (P<0*01).
Blood-gas data were obtained before and after 33 doses of tolazoline in 20 infants (Table 3 ). There was a significant rise of 21 mmHg in Pao2 after tolazoline injection (P<0 .01) which occurred despite a fall in F1O2, while MAP did not change significantly. No significant change in pH, Paco2, or base excess occurred. In the 11 infants who were not shown subsequently to have intracranial haemorrhage or pneumothorax (group A), the mean rise in Pao2 was 26 mmHg compared with the mean rise in Pao2 of 10 mmHg in the 9 infants with intracranial haemorrhage or pneumothorax (group B). This difference is not statistically significant. If the 2 patients with pneumothorax are excluded from group B, the mean rise in Pao2 for the group is 4 mmHg which is significantly different from the rise in group A (P<0 05). When only the response to the first dose of tolazoline is considered, the mean rise in Pao2 after tolazoline was 33 mmHg (P<0*01) which occurred despite of a fall in F1O2, while MAP did not change significantly. In group A the mean rise in Pao2 of 49 mmHg was significantly greater than in group B in which the mean rise was 14 mmHg (P<0 05).
Discussion
Tolazoline hydrochloride is chemically related to the sympathomimetic amines and histamine. It is a short-acting alpha adrenergic blocking agent, but in the doses used in the clinical situation this effect is negligible. It is also a histaminic agent and has a direct nonadrenergic relaxant action upon vascular smooth muscle, the vasodilator effect being greatest in regions where vasoconstriction is most pronounced (Grover et al., 1961) . Tolazoline has been shown to relieve pulmonary vasoconstriction and in this respect it is believed to be most effective in those cases where pulmonary vascular resistance is increased due to a generalised constriction of hypertrophied small muscular arteries (Grover et al., 1961) . This situation is similar to that seen in severe hyaline membrane disease with hypoxaemia, and pulmonary vasospasm has been demonstrated in such infants by Chu et al. (1967) . The possible value of tolazoline in the management of severe hypoxaemia in infants with hyaline membrane disease has been suggested (Goetzman et al., 1976) .
In our 20 deteriorating infants we demonstrated a significant rise in arterial Pao2 in response to tolazoline. The babies acted as their own controls as the drug was given only as a last resort when all other treatments had failed and it was felt that death was imminent. In infants who did not have intracranial haemorrhage or pneumothorax as a cause for their severe refractory hypoxaemia the improvement was more pronounced. The difference in response to tolazoline between the two groups was more marked with the first dose than with subsequent ones.
Of the 10 infants who had an obvious clinical cells through a distended cerebral capillary bed to the cerebrospinal fluid. In neither case presenting in this manner was there apparent abnormality in the coagulation status which has been associated with subarachnoid haemorrhage (Chessells and Wigglesworth, 1971 ). Gastrointestinal problems were not encountered, although a potential hazard from reduced splanchnic flow might be necrotising enterocolitis; abdominal distension and haemorrhage have been well described by Goetzman et al. (1976) .
We agree with Levin et al. (1976) that one definite indication for tolazoline is hypoxaemia with demonstrable difference between upper and lower body Pao2, implying persistence of transitional right-to-left circulation through the ductus arteriosus. This, in fact, occurred in only one baby in our series.
We conclude that there is a place for the use of tolazoline in a severely hypoxaemic infant with hyaline membrane disease who is being ventilated with an inspired oxygen concentration of 100% and in whom the Pao2 is unresponsive to alteration of ventilator settings. In these cases where chest movement is clinically normal and where pneumothorax has been radiologically excluded, tolazoline may have a dramatic effect. 
